selective immunoglobulin A deficiency


Also found in: Wikipedia.

se·lec·tive im·mu·no·glob·u·lin A de·fi·cien·cy

an inherited disorder in which IgA is markedly reduced or absent, resulting in immature IgA-bearing B cells.
References in periodicals archive ?
In the United States, Hizentra is indicated for the treatment of patients with PID, and contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations or components of Hizentra , and in persons with selective immunoglobulin A deficiency who have known antibody against IgA and a history of hypersensitivity.
Role of human tissue transglutaminase IgG and anti-gliadin IgG antibodies in the diagnosis of coeliac disease in patients with selective immunoglobulin A deficiency.
Celiac disease and selective immunoglobulin A deficiency.
Prevalence and clinical features of selective immunoglobulin A deficiency in coeliac disease: an Italian multicentre study.
In the United States, Hizentra is indicated for the treatment of patients with primary immunodeficiency (PI), and contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations or components of Hizentra , and in persons with selective immunoglobulin A deficiency who have known antibody against IgA and a history of hypersensitivity.
Role of human-tissue transglutaminase IgG and anti-gliadin IgG antibodies in the diagnosis of coeliac disease in patients with selective immunoglobulin A deficiency.
In the United States, Hizentra is indicated for the treatment of patients with primary immunodeficiency (PI), and contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations or components of Hizentra, and in persons with selective immunoglobulin A deficiency who have known antibody against IgA and a history of hypersensitivity.
As with all immunoglobulin products, Vivaglobin is contraindicated in individuals with a history of anaphylactic or severe systemic response to immunoglobulin preparations, in the US and Canada also and in persons with selective immunoglobulin A deficiency who have known antibody against IgA.
As with all immune globulin products, the study medication is not recommended for individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A deficiency who have known antibody against IgA.
As with all immune globulin products, Vivaglobin(R) is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A deficiency who have known antibody against IgA.
Full browser ?